drugset
drugset / Trial / NCT05946941

A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome

NCT05946941 ↗

Phase 3 Active not recruiting 774 enrolled Bristol-Myers Squibb
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess the safety and efficacy of two doses of Deucravacitinib in adult participants with Active Sjögren's Syndrome.

Timeline

Start
2023-09-11
Primary completion
2026-11-18
Completion
2028-11-16

Drugs

EvaluationDrugModalityDoseRoute
Subject CRAVACITINIB Small molecule — —

Indications

Sjogren syndrome